Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 115 clinical trials
A Study of MSB2311 in Advanced Solid Tumors

This is a first-in-human (FIH), open-label, Phase 1 dose-Escalation Study of MSB2311, a humanized anti-PD-L1 monoclonal antibody, in subjects with advanced solid tumors. Qualified subjects will be enrolled to receive their assigned dose regimen of MSB2311 until disease progression or intolerable toxicity, withdrawal of consent, or end of study, whichever …

solid tumour
monoclonal antibodies
metastasis
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor

Combinations of Dendritic cell-activated cytokine-induced killer cell (DC-CIK) With chemotherapy treatment may enhance the immune response and stop cancer cells from growing.

psychiatric disorder
metastasis
brain metastases
platelet count
advanced solid tumor
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of MSB0254 Injection in Advanced Solid Tumors

This study was an open, multi-dose dose escalation phase I clinical study to evaluate the safety, tolerability and PK characteristics of MSB0254 in patients with locally advanced or metastatic solid tumors, and to preliminarily measure its anti-tumor efficacy.

solid tumour
metastasis
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

The purpose of this study is to evaluate the safety and efficacy of Surufatinib plus Sintilimab in Patients with Advanced Solid Tumor

  • 0 views
  • 05 Aug, 2020
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276

Patients with refractory and/or recurrent solid tumor have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed. This study attempts to treat these diseases using T cells genetically modified with a 4th generation lentiviral chimeric antigen receptor (4SCAR fused with an inducible apoptotic caspase 9 domain) …

ejection fraction
metastasis
platelet count
growth factor
antibody therapy
  • 0 views
  • 16 Feb, 2024
  • 3 locations
RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

This study is a multi-center, open-label, dose escalation study of RLY-1971 in subjects with advanced or metastatic solid tumors.

metastatic malignant solid tumor
solid tumor
solid tumour
hair thinning
neuropathy
  • 0 views
  • 16 Feb, 2024
  • 4 locations
Study of AMG 650 in Adult Participants With Advanced Solid Tumors

To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

  • 0 views
  • 16 Feb, 2024
  • 3 locations
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

An ascending dose study in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamics and efficacy of APG-1387 in combination with toripalimab. A phase II study of 3 cohorts will be included.

antineoplastic
non-small cell lung cancer
metastasis
hair thinning
EGFR
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients …

adenocarcinoma
lung cancer
non-small cell lung cancer
urothelial carcinoma
squamous cell carcinoma of head and neck
  • 0 views
  • 16 Feb, 2024
  • 4 locations
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in Part 2.

adenocarcinoma
targeted therapy
gnrh
solid neoplasm
castration-resistant prostate cancer
  • 0 views
  • 16 Feb, 2024
  • 7 locations